Halozyme Therapeutics: Steady Growth In A Challenged Market
Halozyme Therapeutics sees strong Q4 2024 growth, driven by ENHANZE platform royalties. Click here to find out why HALO stock ...
Fierce Pharma1d
Roche settles UPenn suit alleging patent infringement by Herceptin, 3 other breast cancer meds
Some three years after the University of Pennsylvania claimed four of Roche’s breast cancer meds infringed its intellectual ...
NHS England4d
Thousands of NHS patients to benefit from ‘take at home’ multiple sclerosis tablet in European first
Thousands of NHS patients in England with multiple sclerosis (MS) are set to benefit from a life-changing ‘take at home’ tablet, as the NHS becomes the first healthcare system in Europe to roll it out ...
pharmaphorum1d
Roche’s Herceptin/Perjeta combo product nears EU approval
Called Phesgo, the new product contains the active substances in Herceptin (trastuzumab) – already facing lower-cost competition in the US and Europe – and Perjeta (pertuzumab), which are both ...
pharmaphorum5d
Daiichi Sankyo partners Alteogen on subcutaneous Enhertu
Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...
National Health Executive3d
Groundbreaking MS treatment to benefit thousands
“Broadening access to cladribine means thousands more patients will benefit from managing their treatment at home rather than regularly attending hospital appointments – as well giving women with MS ...
Yahoo Finance2d
Halozyme Therapeutics, Inc. (HALO)
At close: March 13 at 4:00:01 PM EDT Loading Chart for HALO ...